ProBioGen signs agreement for manufacturing process development of vaccine project
Earlier work has already confirmed the versatility and benefit of ProBioGen’s vaccine development platform
30 Mar 2021
ProBioGen AG has announced the signing of a service agreement for Nobelpharma’s highly relevant vaccine project.
Earlier work confirmed already the versatility and benefit of ProBioGen’s vaccine development platform, consisting of the proprietary, well-proven AGE1.CR.pIX® suspension cell line and its high-performance cell culture medium, for the propagation of Nobelpharma’s virus strain.
Now, ProBioGen applies state-of-the-art technologies and deep expertise to perform the upstream and downstream process development for Nobelpharma's highly relevant vaccine for large-scale manufacturing.
The duck cell line AGE1.CR.pIX was designed to serve the industrial, GMP-compliant production of a wide variety of viruses in large bioreactors and is free of any adventitious agents.
It has already proven its great utility for viral vector production in various clinical trials.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>